Ferumoxytol
- TRADE NAME: Feraheme (AMG Pharma)
- INDICATIONS: Iron deficiency anemia in adults with chronic kidney disease
- CLASS: Iron supplement
- HALF-LIFE: 15 hours
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
None known
PREGNANCY CATEGORY: C
May cause hypersensitivity reactions, hypotension and iron overload. Feraheme may transiently affect magnetic resonance (MRI) imaging for up to 3 months following dosage.
Contra-indicated in patients with evidence of iron overload or anemia not caused by iron deficiency.
Please login to see the rest of this drug profile
SKIN.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
HEMATOLOGIC.
LOCAL.
NEUROMUSCULAR/SKELETAL.
RESPIRATORY.
OTHER.
Page last updated 07/31/2023
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric